DE60129137D1 - Modulierung durch il-tif/interleukin-21 - Google Patents
Modulierung durch il-tif/interleukin-21Info
- Publication number
- DE60129137D1 DE60129137D1 DE60129137T DE60129137T DE60129137D1 DE 60129137 D1 DE60129137 D1 DE 60129137D1 DE 60129137 T DE60129137 T DE 60129137T DE 60129137 T DE60129137 T DE 60129137T DE 60129137 D1 DE60129137 D1 DE 60129137D1
- Authority
- DE
- Germany
- Prior art keywords
- molecules
- nucleic acid
- proteins
- interleukin
- tif
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010054016 IL-TIF IL-10-related T cell-derived inducible factor Proteins 0.000 title 1
- 102100030704 Interleukin-21 Human genes 0.000 title 1
- 102100030703 Interleukin-22 Human genes 0.000 title 1
- 108010074108 interleukin-21 Proteins 0.000 title 1
- 108010074109 interleukin-22 Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 abstract 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000000585 Interleukin-9 Human genes 0.000 abstract 1
- 108010002335 Interleukin-9 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229940118526 interleukin-9 Drugs 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62661700A | 2000-07-27 | 2000-07-27 | |
| PCT/US2001/020485 WO2002010393A2 (en) | 2000-07-27 | 2001-06-27 | Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60129137D1 true DE60129137D1 (de) | 2007-08-09 |
Family
ID=24511131
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60129137T Expired - Lifetime DE60129137D1 (de) | 2000-07-27 | 2001-06-27 | Modulierung durch il-tif/interleukin-21 |
| DE60142861T Expired - Lifetime DE60142861D1 (de) | 2000-07-27 | 2001-06-27 | Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60142861T Expired - Lifetime DE60142861D1 (de) | 2000-07-27 | 2001-06-27 | Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1305419B1 (https=) |
| JP (1) | JP4113773B2 (https=) |
| CN (3) | CN100497628C (https=) |
| AT (2) | ATE365801T1 (https=) |
| AU (1) | AU7303301A (https=) |
| CA (1) | CA2416820A1 (https=) |
| DE (2) | DE60129137D1 (https=) |
| ES (1) | ES2349312T3 (https=) |
| WO (1) | WO2002010393A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US20030170823A1 (en) | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
| US20030023033A1 (en) * | 2001-07-26 | 2003-01-30 | Laure Dumoutier | Novel class II cytokine receptors and uses thereof |
| US20030012788A1 (en) | 2000-07-27 | 2003-01-16 | Jean-Christophe Renauld | Method for influencing kinase pathways with IL-22 |
| US20060083713A1 (en) * | 2000-10-13 | 2006-04-20 | Eli Lilly And Company | Methods of using a human il-17 related polypeptide to treat disease |
| US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| EP1546358A4 (en) | 2002-03-22 | 2006-06-07 | Zymogenetics Inc | ANTI-IL-TIF ANTIBODIES AND METHOD FOR USE ON INFLAMMATION |
| WO2004003156A2 (en) | 2002-07-01 | 2004-01-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Il-21 as a regulator of immunoglobin production |
| EP1562587A4 (en) * | 2002-09-11 | 2006-07-19 | Genentech Inc | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF IMMUNOMOTICS |
| PL376118A1 (en) * | 2002-10-11 | 2005-12-12 | Novo Nordisk A/S | Treatment of allergic conditions by use of il 21 |
| KR20050065590A (ko) * | 2002-10-11 | 2005-06-29 | 노보 노르디스크 에이/에스 | Il 21을 이용한 알레르기 상태의 치료법 |
| ES2354693T3 (es) * | 2003-06-23 | 2011-03-17 | Genetics Institute, Llc | Anticuerpos contra interleucina-22 y usos para ellos. |
| EP1954719A2 (en) | 2005-12-02 | 2008-08-13 | Genentech Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途 |
| TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
| IT1404858B1 (it) | 2011-02-21 | 2013-12-09 | Milano Politecnico | Supporto anti-sismico. |
| US20240026014A1 (en) * | 2020-08-05 | 2024-01-25 | Synthekine, Inc. | Compositions and methods related to receptor pairings |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843697A (en) | 1996-07-17 | 1998-12-01 | University Of Medicine And Dentistry Of New Jersey | Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein |
| DE19848683B4 (de) | 1998-10-22 | 2004-05-06 | Basf Ag | Verbundschichtplatte |
| EP1131333B1 (en) * | 1998-10-26 | 2010-06-02 | Wyeth a Corporation of the State of Delaware | ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF |
| BR0010097A (pt) * | 1999-04-28 | 2002-02-13 | Genetics Inst | Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo |
| AU5047600A (en) * | 1999-05-27 | 2000-12-18 | Schering Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
| US6897292B2 (en) * | 1999-12-03 | 2005-05-24 | Zymogenetics, Inc. | Human cytokine receptor |
-
2001
- 2001-06-27 DE DE60129137T patent/DE60129137D1/de not_active Expired - Lifetime
- 2001-06-27 AU AU7303301A patent/AU7303301A/xx not_active Withdrawn
- 2001-06-27 WO PCT/US2001/020485 patent/WO2002010393A2/en not_active Ceased
- 2001-06-27 AT AT01952260T patent/ATE365801T1/de not_active IP Right Cessation
- 2001-06-27 EP EP01952260A patent/EP1305419B1/en not_active Expired - Lifetime
- 2001-06-27 ES ES07002409T patent/ES2349312T3/es not_active Expired - Lifetime
- 2001-06-27 EP EP07002409A patent/EP1806404B1/en not_active Expired - Lifetime
- 2001-06-27 AT AT07002409T patent/ATE478148T1/de not_active IP Right Cessation
- 2001-06-27 CN CNB2005101169978A patent/CN100497628C/zh not_active Expired - Fee Related
- 2001-06-27 CN CNA2008101764854A patent/CN101423551A/zh active Pending
- 2001-06-27 DE DE60142861T patent/DE60142861D1/de not_active Expired - Lifetime
- 2001-06-27 CA CA002416820A patent/CA2416820A1/en not_active Abandoned
- 2001-06-27 CN CNB018131255A patent/CN100448994C/zh not_active Expired - Fee Related
- 2001-06-27 JP JP2002516309A patent/JP4113773B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4113773B2 (ja) | 2008-07-09 |
| JP2004504842A (ja) | 2004-02-19 |
| CN100448994C (zh) | 2009-01-07 |
| AU7303301A (en) | 2002-02-13 |
| ATE478148T1 (de) | 2010-09-15 |
| EP1806404A1 (en) | 2007-07-11 |
| WO2002010393A2 (en) | 2002-02-07 |
| EP1806404B1 (en) | 2010-08-18 |
| CN1443241A (zh) | 2003-09-17 |
| CN100497628C (zh) | 2009-06-10 |
| ES2349312T3 (es) | 2010-12-29 |
| DE60142861D1 (de) | 2010-09-30 |
| WO2002010393A3 (en) | 2003-01-30 |
| CA2416820A1 (en) | 2002-02-07 |
| ATE365801T1 (de) | 2007-07-15 |
| EP1305419B1 (en) | 2007-06-27 |
| CN1796558A (zh) | 2006-07-05 |
| CN101423551A (zh) | 2009-05-06 |
| EP1305419A2 (en) | 2003-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60129137D1 (de) | Modulierung durch il-tif/interleukin-21 | |
| ATE469911T1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| BRPI0512396A (pt) | polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente | |
| ATE227739T1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
| DE60144145D1 (de) | Subtilisin-variante | |
| CY1112198T1 (el) | Αναλογα κομπστατινης με βελτιωμενη δραστικοτητα | |
| EP1019365A4 (en) | NOVEL NEGATIVELY LOADED MOLECULE DELIVERY COMPOSITIONS | |
| ATE536369T1 (de) | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung | |
| DK1458760T3 (da) | Indfangede bindingsproteiner som biosensorer | |
| NO20043259L (no) | Bindingsproteiner som biosensorer | |
| DK1015586T3 (da) | TIE-receptortyrosinkinaseligandhomologer | |
| DK0912176T3 (da) | Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression | |
| ATE507822T1 (de) | Stabilisierte zusammensetzungen von faktor-vii- polypeptiden | |
| ATE451390T1 (de) | Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys) | |
| ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| WO2005017205A3 (en) | Nucleic acid mapping using linear analysis | |
| EA200401453A1 (ru) | Молекулы распознавания на клеточной поверхности, содержащие иммуноглобулиновый домен | |
| ATE512228T1 (de) | Induzierbare expressionssysteme | |
| DK1536778T3 (da) | Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet | |
| BR0312521A (pt) | Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado | |
| GEAP202516650A (en) | Stabilized pre-fusion hmpv fusion proteins | |
| WO2003050283A3 (en) | A structure for presenting desired peptide sequences | |
| DE60141588D1 (de) | Nukleinsäuresequenz und protein, das eine rolle bei der zellulären alterung spielt | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| DK1465927T3 (da) | BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de |